Dutch research centre secures €265m

The Dutch Centre for Translational Molecular Medicine (CTTM), which is dedicated to the development of technologies in molecular medicine, has announced the completion of €265m funding for translational medical research.

Translational medical research is a paradigm which focuses on translating basic science discoveries into cutting-edge therapeutics; and translating cutting-edge therapeutics into mainstream primary care.

The funding makes the CTTM one of the largest public-private partnerships in the world and one of the world’s leading destinations for translational biomedical research.

The funding was completed with the approval of a prostate cancer research project.

Peter Luijten, CTTM chief scientific officer, said: “The €15m allocated to this prostate cancer project, which brings the total allocated CTMM funding to €265m, should enable the project team to make a real difference to the diagnosis and treatment of a disease hat counts among the biggest killers of men.”

The final project approval has fulfilled the centre’s business plan objectives to establish a public-private consortium to address the world’s most prevalent diseases.

Using the funding, the Netherlands based centre is working to develop technologies that enable the early diagnosis and treatment of the four main areas that cause the highest moralities across the western world, oncology, cardiovascular, neurodegenerative and infectious/auto immune disease.

The 18 project portfolio is 50% funded by the Dutch government, 25% from academia and 25% from industry companies, with more than 100 partners from academia and the industry involved.

Link

Dutch Centre for Translational Molecular Medicine